Sodium oxamate - CAS:565-73-1

您当前的位置：

Sodium oxamate (Synonyms:草氨酸钠;Oxamic acid sodium)

目录号 : KCM14317 CAS No. : 565-73-1 纯度 : ≥95%

产品说明书 SDS 产品使用指南

Sodium oxamate is a derivative of pyruvate that inhibits the conversion of pyruvate to lactate via lactate dehydrogenase, thus disrupting glycolysis. Because cancer cells produce a large amount of energy via aerobic glycolysis, sodium oxamate has been studied as an inhibitor of carbohydrate metabolism in various tumors.

规格	价格	是否有货	数量
500mg		In-stock
1g		In-stock
5g		In-stock
25g		In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

4"-Isovalerylspiramycin I In-stock
Higenamine-d4 hydrochloride In-stock
Adebrelimab In-stock
Tigatuzumab In-stock
Cosdosiran In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

体外研究

Oxamate acid inhibits the proliferation, migration, and invasion of A2780 and SKOV3 cells
Oxamate acid (10 μ M; 24-72 h) exhibits dose-dependent and time-dependent inhibition of cell proliferation in two types of NPC cancer cells
Sodium Oxamate (0-100 mM; 24 hours) induces G2/M phase cell cycle arrest in CNE-1 and CNE-2 cells
Sodium Oxamate (0-100 mM; 48 hours) induces apoptosis in NPC cells through caspase-3 activation and mitochondrial pathway
Sodium Oxamate (0-100 mM; 24 hours) increases ROS levels in NPC cells

Cell Proliferation Assay

Cell Line:	CNE-1 and CNE-2 cells
Concentration:	10 μM
Incubation Time:	24-72 hours
Result:	Showed IC50s of 74.6, 32.4 and 17.8 mM and 62.3, 44.5, 31.6 mM at 24, 48 and 72 h in the CNE-1 and CNE-2 cancer cells, respectively.

体内研究

Sodium Oxamate (intraperitoneal injection; 750 mg/kg； Every time; 3 w) Combined radiation treatment can enhance the tumor suppression effect in vivo.

Animal Model:	Female Balb/c nude mice injected with CNE-1 cells
Dosage:	750 mg/kg
Administration:	Intraperitoneal injection; 750 mg/kg; once daily; 3 weeks
Result:	Inhibited the tumor growth when compared to either oxamate alone or irradiation alone.

分子式

C₂H₂NNaO₃

分子量

111.03

CAS号

565-73-1

中文名称

草氨酸钠

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

2-8°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:

DMSO : 3.23 mg/mL (29.09 mM; ultrasonic and warming and adjust pH to 5 with HCl and heat to 60°C)

H₂O : 50 mg/mL (450.33 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	9.0066 mL	45.0329 mL	90.0658 mL
5 mM	1.8013 mL	9.0066 mL	18.0132 mL
10 mM	0.9007 mL	4.5033 mL	9.0066 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶